The Drug Efficacy Study

[The following description was adapted from former Division of Medical Sciences Chairman R. Keith Cannan's history of the DES, published in the May 1968 NAS News Report]

The Drug Efficacy Study of the National Research Council's Division of Medical Sciences, which was tasked with evaluating the medical effectiveness of 3,000-4,000 drugs introduced between 1938 and 1962, was undertaken in April 1966 at the request of the Food & Drug Administration (FDA) and its thennew Commissioner James L. Goddard. The stimulus to the study was the 1962 Kefauver-Harris Amendment to the Food Drug & Cosmetic Act of 1938. The Amendment required that in addition to being proven to be safe, drugs must be shown to be effective in regard to the therapeutic claims made for them.

Guidelines for the conduct of the study were developed by a Policy Advisory Committee (PAC), the membership of which derived from academic and professional medicine and its major specialties, as well as from pharmacology, industry, and medical sociology. The actual work of drug evaluation was assigned to 180 specialists assembled into thirty panels covering the main categories of drug applications. The panels sought evidence of drug efficacy from four main sources: 1) Briefs submitted by the sponsor of the drug; 2) additional evidence directly solicited from the sponsor; 3) the files of the FDA; and 4) pertinent medical literature brought in by the panelists. Each claim for a drug was subjected to a separate evaluation leading to a decision as to the drug's efficacy, thus compelling the panels to make literally tens of thousands of such decisions. The panels then submitted the reports of their evaluations to the PAC, which in turn transmitted the reports to the FDA. A final report was issued by the DES in 1969; in addition, the panels' reports were published verbatim in the Federal Register after they were received by the FDA.

The records of the Drug Efficacy Study contain correspondence, reports, meeting minutes, press clippings, and other records documenting the activities of the DES. The papers originated in the offices of the DES and the Division of Medical Sciences. The size of the collection is approximately 3.5 linear feet, spanning the dates of 1963-1974 with the bulk of the collection dating from 1966-1969.

SERIES 1: DRUG EFFICACY STUDY (DES)

- Ad hoc Committee on Drug Efficacy Review: Meeting: 20 Apr 1966
- Agreement on Transmittal of New Drug Applications from FDA to NAS: 1966
- Aid to FDA in Implementing Recommendations: 1967-1968
- Beginning of Program: 1966
- Categorization of Drugs: Aug 1966
- Chronology: 1968
- Committees
 - Drug Categorization: 1966
- Conferences
 - On Guidelines
 - Assembly of Organizational Delegates: Proceedings: 1966
 - Report of Pharmaceutical Manufacturers Association (PMA): 1966
 - General: 1966

For Drugs Ranked "Effective, But": 5 Apr 1971

• Contract: 1966-1968

• Critiques of DES by Executive Secretaries: 1966-1968

"Drug Efficacy Study of the NAS-NRC"

o Smith R G [History of DES]: 1968

• End of Program: 1969

• FDA Interim Index to Evaluations Published in Federal Register for NAS-NRC Reviewed

Prescription Drugs: 1974

General Statements: 1967-1968

Guidelines: 1966

o General: 1966-1967

• Ineffective Drugs

o Roster: 1969-1972

Information Exchanges

Veterinary Drug Study: 1966-1968
 Information Releases by FDA: 1967-1968

Invitations to Panel Members to Testify in Legal Proceedings

o 1970

US Vitamin v Finch: 1969

o Bentyl: 1968

Meetings

o Listings: 1966-1968

Staff Meetings: 1966-1968

Memoranda

o Executive Secretaries: 1966-1968

Panel Chairmen & Members: 1966-1968

Policy Advisory Committee (PAC): 1966-1968

• Organizing Committee: 1966

Policies

Panel Members Testifying in Legal Proceedings: 1968

Problems

Clarification of "Effective But" Ranking: 1971-1972

Meeting: 5 Apr 1971

Memorandum to Panel Chairmen: Jan 1971

Legal Status of Package Inserts [Modell Editorial "FDA Censorship"]: 1967

o Therapeutic Equivalence of Generic Drugs: 1967-1969

• Progress Reports: 1966-1969

• Reporting Forms: 1966

Retention of Records: 1967-1968

• Special Statements: 1967-1968

Speeches on History & Work of DES by Cannan Gilman & Trexler: 1966-1968

Structure: 1966-1969General: 1966-1974

SERIES 2: DES PANELS

Administrative Procedures: 1966-1967

- Allergy
 - Meetings: 1966-1968Membership: 1966General: 1966-1969
- Anesthesia
 - Membership: 1966General: 1966-1969
- Anti-Infectives
 - o (I): 1966-1969
 - (II): Consultants: 1967
 (II): General: 1966-1968
 (III): Membership: 1966
 (III): General: 1966-1969
 (IV): 1966-1969
 - (IV): 1966-1969(V): 1966-1968
 - Membership: 1966-1967
- Antineoplastic
 - Membership: 1966General: 1966-1968
- Anti-Parasitic
 - Membership: 1966General: 1966-1968
- Cardiovascular
 - (I): Membership: 1966-1967
 (I): General: 1966-1968
 (II): Membership: 1967
 (II): General: 1967-1969
- Chairmen
 - Rosters: 1966-1968Meetings: First: 9 Sep 1966
- Consultants
 - Surgery: 1967Urology: 1967-1969
- Dentistry
 - Membership: 1966General: 1966-1969
- Dermatology
 - (I): Membership: 1966-1969
 (I): General: 1966-1969
 (II): Membership: 1966-1967
 (II): General: 1966-1969
 (III): Membership: 1967
 (III): General: 1967-1969
- Diagnostic Agents
 - Membership: 1966General: 1966-1968
- Endocrine Disturbances

o Membership: 1966

o General: 1966-1968

• Executive Secretaries: 1966-1968

Fluid & Electrolyte Imbalance

Membership: 1966-1967General: 1966-1968

Gastroenterology

(I): Membership: 1966(I): General: 1966-1969

(II): Membership: 1966-1967(II): General: 1966-1968

Hematology

Membership: 1966General: 1966-1969

• Interviews with Chairmen: 1967

Meetings

o Listings: 1966-1968

Membership

o Comments on DES Experience: 1969

Comments on Topics for Final Report: 1969

Excerpts: 1969End of Term Letters: 1969

Nominations

By Panel Chairmen: 1966

Of Chairmen by Professional & Scientific Societies: 1966

o Release of Names of Panel Members to Congress: 1968

General: 1966-1969

Metabolic

Membership: 1966General: 1966-1968

Neurological

Membership: 1966-1967General: 1966-1969

Ophthalmology

Membership: 1966General: 1966-1968

Psychiatric

Consultants: 1967-1968
 Membership: 1966-1967
 General: 1966-1971

Relief of Pain

Membership: 1966-1967General: 1966-1968

• Reproductive System

Membership: 1966General: 1966-1968

Respiratory Disturbances

Membership: 1966-1967General: 1966-1968

• Rheumatic Diseases

Consultants: 1967
 Membership: 1966
 General: 1966-1969

Surgery

Establishment: 1967
 Membership: 1967-1968
 General: 1967-1969

• General: 1966-1967

SERIES 3: DES POLICY ADVISORY COMMITTEE (PAC)

- Executive Committee
 - Briefing for Pharmaceutical Manufacturers Association on Status of Drug Efficacy Study:
 31 Oct 1967
 - Meeting to Consider Classification of Anti-Infective Combination Drugs: 24 May 1968
 - Meeting with Representatives of FDA: 30 Nov 1967
- Meetings
 - Joint with Panel Chairmen: 17 May 1967
 - o With FDA on Interpretation of DES Reports: 23 Jan 1969

Fourth: 6 Mar 1969Third: 27 Mar 1968Second: 12 Jan 1967

o First [DES Meeting with Representatives of FDA]: 16 Dec 1966

Membership

Appointments: 1966-1968General: 1966-1967

Resolution on Publications by Panel Members: 1968

• General: 1966-1968

SERIES 4: DES REPORTS

Categorization of Final Reports: 1968

• Final: 1969

Distribution: 1969Preparation: 1968-1969

Transmittal to Panel Members: 1969

o General: 1968-1970

Reevaluation of Drugs Ranked "Effective But"

Allergy: 1971
Anesthesia: 1971
Anti-Infective: 1971
Antineoplastic: 1971
Antiparasitic: 1971
Cardiovascular: 1971

o Dentistry: 1971

o Fluid & Electrolyte Imbalance: 1971

o Gastroenterological: 1971

Hematologic: 1971
Metabolic: 1971
Neurological: 1971
Ophthalmologic: 1971
Relief of Pain: 1971

Reproductive System: 1971
 Respiratory Disturbances: 1971
 Rheumatic Diseases: 1971

Surgery: 1971General: 1971

• Release: 1967-1968

Submissions

1-6: 1968
7-10: 1968
11-15: 1968
16-19: 1968

o 20-25: 1968-1969

Summaries: 1968White Papers

o Anti-Infective Combinations: 1968-1969

• General: 1967-1968

SERIES 5: DES NAME FILES

• Cannan R K [Special Assistant to NAS President]: 1963-1968

• De Haen P [Drugs in Use Index Card System]: 1964-1967

• Gilman A [PAC Exec Com Member]: 1967-1968

• Goddard J L [FDA Commissioner]: 1966-1968

• Middleton W S [DES Chairman]

0 1966-1968

o Drug Research Board (DRB) Correspondence: 1963-1965

Seevers M: 1967

• Shirkey H C [PAC Member]: 1966-1969

• Smith R G [FDA Liaison to NAS]: 1966-1968

SERIES 6: PRESS COVERAGE

Press Coverage

News Articles: 1966-1969General: 1967-1970